Press and Announcements

Please check back frequently for news, announcements, and events.



ipeline Praetego’s novel small molecules have demonstrated preclinical proof of efficacy in a variety of neurodegenerative and diabetic microvascular disease models. Our Alzheimer’s Disease program leads the pipeline and is complemented by our research in Diabetic Peripheral Neuropathy and Diabetic Retinopathy, both implicated in neurodegeneration. Read More >